ReviewImmunotherapy2015
The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy.
Review in Immunotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes.Obesity (Silver Spring, Md.) · 2021Trial
- IL27 expression and IL27RA-dependent cellular responses are associated with biochemical recurrence and immune-regulatory features in prostate cancer.Frontiers in immunology · 2026Article
- The expression and clinical significance of IL-27 and Foxp3 in oral squamous cell carcinoma.BMC cancer · 2025Article
- Expressions of Interleukin-27 in Oral Lichen Planus, Oral Leukoplakia, and Oral Squamous Cell Carcinoma.Inflammation · 2022Article
- The Yin-Yang Dynamics in Cancer Pharmacogenomics and Personalized Medicine.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Engineering a potent receptor superagonist or antagonist from a novel IL-6 family cytokine ligand.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Article
- Intra-Tumoral Delivery of IL-27 Using Adeno-Associated Virus Stimulates Anti-tumor Immunity and Enhances the Efficacy of Immunotherapy.Frontiers in cell and developmental biology · 2020Article
- Interleukin 27 Protects From Gastric Atrophy and Metaplasia During Chronic Autoimmune Gastritis.Cellular and molecular gastroenterology and hepatology · 2020Article
- Cancer Cell enters reversible quiescence through Intracellular Acidification to resist Paclitaxel Cytotoxicity.International journal of medical sciences · 2020Article
- Interleukin-27 Functional Duality BalancesFrontiers in immunology · 2020Review
- Is AAV-delivered IL-27 a potential immunotherapeutic for cancer?American journal of cancer research · 2020Review
- Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers.Journal of blood medicine · 2019Article
- Investigation of Interleukin-27 in the Sera of Nonmelanoma Skin Cancer Patients.Dermatology research and practice · 2018Article
- Interleukin-27 signalling induces stem cell antigen-1 expression in T lymphocytes in vivo.Immunology · 2017Article
- Dual Roles of IL-27 in Cancer Biology and Immunotherapy.Mediators of inflammation · 2017Review
- Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?Journal of immunology (Baltimore, Md. : 1950) · 2016Review
- Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells.Oncotarget · 2016Article
- Systemic delivery of IL-27 by an adeno-associated viral vector inhibits T cell-mediated colitis and induces multiple inhibitory pathways in T cells.Journal of leukocyte biology · 2016Article
- Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer.American journal of translational research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Accumulating evidences from animal studies have indicated that both endogenous and exogenous IL-27, an IL-12 family of cytokine, can increase antitumor T-cell activities and inhibit tumor growth. IL-27 can modulate Treg responses, and program effector T cells into a unique T-effector stem cell (TSEC) phenotype, which enhances T-cell survival in the tumor microenvironment. However, animal studies also suggest that IL-27 induces molecular pathways such as IL-10, PD-L1 and CD39, which may downregulate tumor-specific T-cell responses. In this review paper, we will discuss the Yin and Yang aspects of IL-27 in the induction of tumor-specific T-cell responses, and the potential impacts of these functions of IL-27 in the design of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.